Clinical Trial

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
Protocol Amendment History 2 changes
notable Trial sites expanded: 17 -> 22 locations 2026-07-09
critical Primary endpoint(s) modified 2026-04-07
Trial Details
NCT Number NCT06193889
Lead Sponsor Kyverna Therapeutics
Conditions Myasthenia Gravis, Generalized Myasthenia Gravis
Enrollment 66 participants
Start Date 2024-08-28
Primary Completion 2027-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-29